References
- Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005;90:3927–32
- Kavanagh-Wright L, Smith TP, Gibney J, McKenna J. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol 2009;70:599–605
- Zgliczyński W, Zdunowski P. Hyperprolactinaemia – pitfalls in PRL assessment. Endokrynol Pol – Pol J Endocrinol 2005;56:980–5
- The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
- Germano L, Mormile A, Filtri L, et al. Evaluation of polyethylene glycol precipitation as screening test for macroprolactinemia using Architect immunoanalyser. IBS 2005;20:402–7
- Vilar L, Moura E, Canadas V, et al. Prevalence of macroprolactinemia among 115 patients with hyperprolactinemia. Arq Bras Endocrinol Metab 2007; 51:86–91
- Mounier C, Trouillas J, Claustrat B, et al. Macroprolactinaemia associated with prolactin adenoma. Hum Reprod 2003;18:853–7
- McKenna TJ. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf) 2009;71:466–9
- Hauache OM, Rocha AJ, Maia AC Jr, et al. Screening for macroprolactinaemia and pituitary imaging studies. Clin Endocrinol (Oxf) 2002;57:327–31
- Hattori N, Adachi T, Ishihara T, Shimatsu A. The natural history of macroprolactinaemia. Eur J Endocrinol 2012;166:625–9
- Lewandowski KC, Gąsior-Perczak D, Kowalska A, Lewiński A. Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease. Thyroid Res 2012;5:1–3
- Tamer G, Telci A, Mert M, et al. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine 2012;41:138–43
- Valette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581–8
- Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006;65:524–9
- Donadio F, Barbieri A, Angioni R, et al. Patients with macroprolactinaemia: clinical and radiological features. Eur J Clin Invest 2007;37:552–7
- Glezer A, D’Alva CB, Salgado LR, et al. Pitfalls in pituitary diagnosis: peculiarities of three cases. Clin Endocrinol (Oxf) 2002;57:135–9
- Robin G, Catteau-Jonard S, Young J, Dewailly D. Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality? Gynecol Obstet Fertil 2011;39:141–5
- Filho RB, Domingues L, Naves L, et al. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol 2007;23:267–72
- Su HW, Chen CM, Chou SY, et al. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia. Gynecol Endocrinol 2011;27:55–62
- Beda-Maluga K, Pisarek H, Komorowski J, et al. The detection of macroprolactin by precipitation and ultrafiltration methods. Endokrynol Pol (Polish J Endocrinol) 2011;62:529–36
- Yavasoglu I, Kucuk M, Coskun A, et al. Polycystic ovary syndrome and prolactinoma association. Intern Med 2009;48:611–3